LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that VIZZ is now available through a convenient telehealth platform, providing the convenience of an integrated online evaluation by independent licensed eye care providers (“ECPs”), epharmacy prescription fulfillment and home delivery. Accessible through VIZZ.com , the integrated telehealth platform connects patients with an independent network of licensed eye care professionals who will evaluate patient telehealth eligibility based upon their medical history. Prescriptions will be automatically routed and fulfilled by LENZ’s epharmacy partner providing a seamless and convenient consumer journey from product interest to home delivery. Launch of the telehealth channel will be promoted alongside the Company’s ‘Tired of Reading Glasses‘ campaign featuring brand spokesperson Sarah Jessica Parker through both a national television advertising campaign and d...